Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Thrombosis Research|June 11, 2026
Anticoagulation in end-stage renal diseaseMaya D'Angelo, Thomas A MavrakanasExpert Review of Cardiovascular Therapy|July 4, 2015
Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?Thomas A Mavrakanas, Yiannis S ChatzizisisCurrent Opinion in Nephrology and Hypertension|September 17, 2016
Cardiovascular complications in chronic dialysis patientsThomas A Mavrakanas, David M CharytanCanadian Journal of Diabetes|April 1, 2018
Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor BlockersThomas A Mavrakanas, Mark L LipmanAmerican Journal of Nephrology|April 15, 2026
Mineralocorticoid Receptor Antagonists in DialysisElias John Elenjickal, Thomas A MavrakanasPharmacology & Therapeutics|April 11, 2015
Bivalirudin in stable angina and acute coronary syndromesThomas A Mavrakanas, Yiannis S ChatzizisisKidney360|December 14, 2022
Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial FibrillationThomas A Mavrakanas, David M CharytanPharmacology & Therapeutics|October 7, 2020
Mineralocorticoid receptor antagonists in patients with chronic kidney diseaseCosimo Cosimato, Thomas Agoritsas, Thomas A MavrakanasCanadian Journal of Diabetes|December 3, 2014
Endogenous endophthalmitis in a patient with diabetes and foot osteomyelitisThomas A Mavrakanas, Raoul de Haller, Jacques PhilippeClinical Journal of the American Society of Nephrology : CJASN|May 24, 2020
Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial FibrillationThomas A Mavrakanas, Katherine Garlo, David M CharytanPageof 7